Development, optimization, and evaluation of Cisplatin-loaded PLGA nanoparticles

Purushothaman Bhuvaneshwaran; Ramaiyan Velmurugan

doi:10.24294/can.v5i2.1768

Development, optimization, and evaluation of Cisplatin-loaded PLGA nanoparticles

Purushothaman Bhuvaneshwaran, Ramaiyan Velmurugan

Article ID: 1768
Vol 5, Issue 2, 2022

VIEWS - 493 (Abstract) 391 (PDF)

Abstract

Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. Cisplatin-loaded nanoparticle formulations were optimized utilizing response surface methods and the central composite rotating design model. This study employed a central composite rotatable design with a three-factored factorial design with three tiers. Three independent variables namely drug polymer ratio, aqueous organic phase ration, and stabilizer concentration were used to examine the particle size, entrapment efficiency, and drug loading of cisplatin PLGA nanoparticles as responses. The results revealed that this response surface approach might be able to be used to find the best formulation for the cisplatin PLGA nanoparticles. A polymer ratio of 1:8.27, organic phase ratio of 1:6, and stabilizer concentration of 0.15 were found to be optimum for cisplatin PLGA nanoparticles. Nanoparticles made under the optimal conditions found yielded a 112 nm particle size and a 95.4 percent entrapment efficiency, as well as a drug loading of 9 percent. The cisplatin PLGA nanoparticles tailored for scanning electon microscopy displayed a spherical form. A series of in vitro tests showed that the nanoparticle delivered cisplatin progressively over time. According to this work, the Response Surface Methodology (RSM) employing the central composite rotatable design may be successfully used to simulate cisplatin-PLGA nanoparticles.

Keywords

Cisplatin; PLGA; Nanoparticles; Response Surface Methodology; Central Composite Rotatable Design

Full Text:

PDF

References

1. Attia MF, Anton N, Wallyn J, et al. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumor sites. Journal of Pharmacy and Pharmacology 2019; 71(8): 1185–1198.

2. Danaei M, Dehghankhold M, Ataei S, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 2018; 10(2): 57.

3. Shehata T, Kimura T, Higaki K, et al. In-vivo disposition characteristics of PEG niosome and its interaction with serum proteins. International Journal of Pharmaceutics 2016; 512(1): 322–328.

4. Kreuter J, Hekmatara T, Dreis S, et al. Covalent attachment of apolipoprotein AI and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. Journal of Controlled Release 2007; 118(1): 54–58.

5. Jiang W, Kim BYS, Rutka JT, et al. Advances and challenges of nanotechnology-based drug delivery systems. Expert Opinion on Drug Delivery 2007; 4(6): 621–633.

6. Lövestam G, Rauscher H, Roebben G, et al. Considerations on a definition of nanomaterial for regulatory purposes. Joint Research Centre (JRC) Reference Reports. Luxembourg: Publications Office of the European Union; 2010. p. 00–41.

7. Zeng X, Tao W, Wang Z, et al. Docetaxel-loaded nanoparticles of dendritic amphiphilic block copolymer H40-PLA-b-TPGS for cancer treatment. Particle & Particle Systems Characterization 2015; 32(1): 112–122.

8. Venkatasubbu GD, Ramasamy S, Avadhani GS, et al. Surface modification and paclitaxel drug delivery of folic acid modified polyethylene glycol functionalized hydroxyapatite nanoparticles. Powder Technology 2013; 235: 437–442.

9. Yang S, Zhou L, Su Y, et al. One-pot photoreduction to prepare NIR-absorbing plasmonic gold nanoparticles tethered by amphiphilic polypeptide copolymer for synergistic photothermal-chemotherapy. Chinese Chemical Letters 2019; 30(1): 187–191.

10. Peng Y, Nie J, Cheng W, et al. A multifunctional nanoplatform for cancer chemo-photothermal synergistic therapy and overcoming multidrug resistance. Biomaterials Science 2018; 6(5): 1084–1098.

11. Reis CP, Neufeld RJ, Ribeiro AJ, et al. Nanoencapsulation I: Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine: Nanotechnology, Biology and Medicine 2006; 2(1): 8–21.

12. Rao JP, Geckeler KE. Polymer nanoparticles: Preparation techniques and size-control parameters. Progress in Polymer Science 2011; 36(7): 887–913.

13. Pal SL, Jana U, Manna PK, et al. Nanoparticle: An overview of preparation and characterization. Journal of Applied Pharmaceutical Science 2011; 1(6): 228–234.

14. Vaughn DJ. Paclitaxel and carboplatin in bladder cancer: Recent developments. European Journal of Cancer 2000; 36: 7–12.

15. Yan X, Gemeinhart R A. Cisplatin delivery from poly (acrylic acid-co-methyl methacrylate) microparticles. Journal of Controlled Release 2005; 106(1–2): 198–208.

16. Cvitkovic E. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treatment Reviews 1998; 24(4): 265–281.

17. Van Leeuwen BL, Kamps WA, Jansen HWB, et al. The effect of chemotherapy on the growing skeleton. Cancer Treatment Reviews 2000; 26(5): 363–376.

18. Gamal Eid A, Uddin N, Girgis S. Formulation and optimization of biodegradable insulin loaded nanoparticles. European Journal of Biotechnology and Bioscience 2019; 7(4): 10–21.

19. Zhang X, Liu J, Qiao H, et al. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technology 2010; 197(1–2): 120–128.

20. Avgoustakis K, Beletsi A, Panagi Z, et al. PLGA–mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. Journal of Controlled Release 2002; 79(1–3): 123–135.

21. Agrahari V, Kabra V, Trivedi P. Development, optimization and characterization of nanoparticle drug delivery system of Cisplatin. 13th International Conference on Biomedical Engineering; 2008 Dec 3–6; Singapore. Heidelberg: Springer; 2009. p. 1325–1328.

22. Zhang X, Liu J, Qiao H, et al. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technology 2010; 197(1–2): 120–128.

23. Nair KGS, Velmurugan R, Sukumaran SK. Formulation and optimization of ansamycin-loaded polymeric nanoparticles using response surface methodology for bacterial meningitis. BioNanoScience 2020; 10(1): 279–291.

24. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Advanced Drug Delivery Reviews 2012; 64: 83–101.

25. Tadros TF, Vincent B. Influence of temperature and electrolytes on the adsorption of poly (ethylene oxide)-poly (propylene oxide) block copolymer on polystyrene latex and on the stability of the polymer-coated particles. The Journal of Physical Chemistry 1980; 84(12): 1575-1580.

26. Krishnamachari Y, Madan P, Lin S. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. International Journal of Pharmaceutics 2007; 338(1–2): 238–247.

DOI: https://doi.org/10.24294/can.v5i2.1768